Psoriasis is a chronic immune-mediated disease with multiple cardiometabolic comorbidities. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), widely used for metabolic conditions, are being evaluated for their potential role in psoriasis. An evidence-informed narrative synthesis from the US National Psoriasis Foundation Medical Board, published in JAMA Dermatology, summarized emerging data and practical considerations for their use.

GLP-1 RAs have been associated with reductions in Psoriasis Area and Severity Index (PASI) scores. Reported relative reductions range from approximately 40% to 80%, with parallel improvements in quality of life. These findings have been observed mainly in patients with obesity or type 2 diabetes mellitus. Most available studies are small, with 7 to 48 patients, short-term up to 6 months, and lack control groups.

Semaglutide and liraglutide have been associated with reductions in C-reactive protein, interleukin-6, lipid levels, and visceral adiposity. In small translational cohorts, PASI improvement has been correlated with reductions in superficial adiposity and dermal γδ T-cell density. GLP-1 RAs have been used safely with methotrexate, cyclosporine, and biologics.

Adverse effects are mainly transient gastrointestinal symptoms. Pancreatitis and gallbladder events are rare. These findings reflect early evidence from small and largely uncontrolled studies. Current evidence supports consideration of adjunctive use in selected patients with metabolic comorbidities. Larger randomized clinical trials are required to confirm efficacy and safety.